title: Stop Flow in abdominal and pelvic cancer relapses.
abstract: To determinate MTD, DLT and safe doses for phase II study, a dose finding study with Mitomycin and Adriamycin Stop-Flow administration was carried out. A phase II study focused on resectability of pelvic colorectal relapses is in progress. From November 1995, 84 pts, 52 male and 32 female (94 treatments), with advanced not resectable abdominal (14 pts) or pelvic (70 pts) relapses, and resistant to previous systemic chemotherapy, were enrolled in the study. 46 pts entered the phase I-early phase II study, while subsequently 38 pts were recruited in ongoing phase II study. Safe dose were: MMC 20 mg/mq and ADM 75 mg/mq. The phase II study focused on colorectal relapses registered very promising responses: 90% pain control, 1 pCR and 26 PR / 63 (OR 43%), 8 NC (13%) 9/27 responder patients (33%) obtained a complete resectability of colorectal relapses. Stop-Flow is a safe and feasible technique very useful as a palliation treatment.
authors.affiliation: Med Onc B INT Naples, Cagliari University, Italy. roberta.formato@tin.it
authors.forename: Rosario Vincenzo
authors.initials: RV
authors.lastname: Iaffaioli
authors.forename: Gaetano
authors.initials: G
authors.lastname: Facchini
authors.forename: Anna
authors.initials: A
authors.lastname: Tortoriello
authors.forename: Feliciano
authors.initials: F
authors.lastname: Crovella
authors.forename: Giovannni
authors.initials: G
authors.lastname: Romano
authors.forename: Roberta
authors.initials: R
authors.lastname: Formato
authors.forename: Michele
authors.initials: M
authors.lastname: Santangelo
authors.forename: Emiddio
authors.initials: E
authors.lastname: Barletta
authors.forename: Francesco
authors.initials: F
authors.lastname: Fiore
authors.forename: Vittorio
authors.initials: V
authors.lastname: Iaccarino
authors.forename: Bruno
authors.initials: B
authors.lastname: Memoli
authors.forename: Roberto
authors.initials: R
authors.lastname: D'Angelo
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Pilati
authors.forename: Riccardo
authors.initials: R
authors.lastname: Rossi
authors.forename: Stefano
authors.initials: S
authors.lastname: Guadagni
authors.forename: Marcello
authors.initials: M
authors.lastname: Deraco
authors.forename: Sandro
authors.initials: S
authors.lastname: Pignata
authors.forename: Bruno
authors.initials: B
authors.lastname: Daniele
authors.forename: Gerardo
authors.initials: G
authors.lastname: Rosati
authors.forename: Bruno
authors.initials: B
authors.lastname: Massidda
authors.forename: Giovanni
authors.initials: G
authors.lastname: Mantovani
authors.forename: Enrico
authors.initials: E
authors.lastname: Di Salvo
authors.forename: Nicola
authors.initials: N
authors.lastname: Marzano
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Memeo
authors.forename: Valerio
authors.initials: V
authors.lastname: Parisi
authors.forename: Giorgio
authors.initials: G
authors.lastname: Mallarini
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Colucci
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D010386:Pelvic Neoplasms / Q000628:therapy*; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; D004317:Doxorubicin